Pharmaceutical company Allergan Aesthetics, an AbbVie company, has announced that the European Commission has approved trenibotulinumtoxinE ‘Boey’ in Europe.
The company shares that Boey is the first rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe for the temporary improvement of glabellar lines in adult patients.
The company shares that results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks. Allergan Aesthetics, an AbbVie company, adds that Boey offers a differentiated treatment option for patients who are curious about facial injectables. This European approval follows approval in Canada in June 2026.
Darin Messina, senior vice president and global head of aesthetics research and development at AbbVie, commented: “The EU approval of Boey marks an important step forward for our development programme and builds on the momentum we’ve established with Health Canada’s approval earlier this year. This milestone reflects the scientific rigor behind Boey and reinforces our commitment to advancing innovative options as we work to bring this treatment to healthcare.”